

# STN STRUCTURE SEARCH

10/78/928

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623ZCT

PASSWORD:


TERMINAL (ENTER 1, 2, 3, OR 7):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
 NEWS 2 "Ask CAS" for self-help around the clock  
 NEWS 3 DEC 05 CASREACT(R) - Over 10 million reactions available  
 NEWS 4 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE  
 NEWS 5 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER  
 NEWS 6 DEC 14 CA/Caplus to be enhanced with updated IPC codes  
 NEWS 7 DEC 21 IPC search and display fields enhanced in CA/Caplus with the IPC reform  
 NEWS 8 DEC 23 New IPCs SEARCH, DISPLAY, and SELECT fields in USPATFULL/USPAT2  
 NEWS 9 JAN 13 IPC 8 searching in IPAT, IPIDUS, and IPICDB  
 NEWS 10 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC  
 NEWS 11 JAN 17 Pre-1988 INPI data added to MARPAT  
 NEWS 12 JAN 17 IPC 8 in the WPI family of databases including WPIFV  
 NEWS 13 JAN 30 Saved answer limit increased  
 NEWS 14 JAN 31 Monthly current-awareness alert (SDI) frequency added to TULSA  
 NEWS 15 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results  
 NEWS 16 FEB 22 Status of current MO (PCT) information on STN  
 NEWS 17 FEB 22 The IPC thesaurus added to additional patent databases on STN  
 NEWS 18 FEB 22 Updates in EPPULL; IPC 8 enhancements added  
 NEWS 19 FEB 27 New STN AnaVist pricing effective March 1, 2006  
 NEWS 20 FEB 28 MEDLINE/LMEDLINE reload improves functionality  
 NEWS 21 FEB 28 TOXCENTER reload with enhancements  
 NEWS 22 FEB 28 REGISTRY/ZREGISTRY enhanced with more experimental spectral property data  
 NEWS 23 MAR 01 INSPEC reload and enhanced  
 NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENH) AND V6.0c(Jp), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V6.0 AND V6.01 USERS CAN OBTAIN THE UPGRADE TO V6.01a AT <http://download.cas.org/express/v6.0-Discover/>  
 NEWS HOURS STN Operating Hours Plus Help Desk Availability  
 NEWS INTER General Internet Information  
 NEWS LOGIN Welcome Banner and News Items  
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may



chain nodes :  
 10 11 12 20  
 ring nodes :  
 1 2 3 4 5 6 7 8 9 13 14 15 16 17 18  
 chain bonds :  
 1-11 2-10 4-20 8-12 9-13  
 ring bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 13-14 13-18 14-15 15-16 16-17 17-18  
 exact/norm bonds :  
 1-2 1-6 2-3 3-4 4-5 4-20 5-6 5-7 6-9 7-8 8-9  
 exact bonds :  
 1-11 2-10 8-12 9-13  
 normalized bonds :  
 13-14 13-18 14-15 15-16 16-17 17-18

G1:C,H,O,S,P

Match level :  
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS  
 11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 20:CLASS

L1 STRUCTURE UPLOADED

=> que L1

L2 QUE L1

=> d 12

L2 HAS NO ANSWERS

L1 STR

result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 11:42:29 ON 02 MAR 2006

FILE	COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST		0.21	0.21

FILE 'REGISTRY' ENTERED AT 11:42:37 ON 02 MAR 2006  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 MAR 2006 HIGHEST RN 875609-25-9  
 DICTIONARY FILE UPDATES: 1 MAR 2006 HIGHEST RN 875609-25-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
 \* The CA roles and document type information have been removed from \*  
 \* the IDE default display format and the ED field has been added, \*  
 \* effective March 20, 2005. A new display format, IDERL, is now \*  
 \* available and contains the CA role and document type information. \*  
 \*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.


REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> Uploading C:\Program Files\Stnexp\Queries\IMIDAZOPYRAZINE KINASE INHs.str



Structure attributes must be viewed using STN Express query preparation.  
 L2 QUE ABB=ON PLU=ON L1

=> # 12  
 SAMPLE SEARCH INITIATED 11:43:05 FILE 'REGISTRY'  
 SAMPLE SCREEN SEARCH COMPLETED - 388 TO ITERATE

100.0% PROCESSED	388 ITERATIONS	16 ANSWERS
SEARCH TIME: 00.00.01		

FULL FILE PROJECTIONS:	ONLINE	**COMPLETE**
BATCH	**COMPLETE**	
PROJECTED ITERATIONS:	6579 TO	8941
PROJECTED ANSWERS:	80 TO	560

L3 16 SEA SSS SAM L1

FILE	COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST		0.44	0.65

FILE 'CAPLUS' ENTERED AT 11:43:10 ON 02 MAR 2006  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Mar 2006 VOL 144 ISS 10  
 FILE LAST UPDATED: 1 Mar 2006 (20060301/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.  
They are available for your review at:


<http://www.cas.org/infopolicy.html>

-- s 13  
L4 2 L3  
-- d 1-2 ibib abs

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2005:134601 CAPLUS  
DOCUMENT NUMBER: 142:134621  
TITLE: Preparation of aryl-substituted 8-aminoarylimidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer and other conditions  
INVENTOR(S): Sun, Connie Li; Liang, Congxin; Huang, Ping; Harris, G. Davis; Guan, Huiping  
PATENT ASSIGNEE(S): Sugan, Inc., USA  
SOURCE: U.S. Pat. Appl. Publ., 119 pp., Cont.-in-part of U.S. Ser. No. 781,928.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005009832	A1	20050113	US 2004-845586	20040514
US 2004220189	A1	20041104	US 2004-781928	20040220
PRIORITY APPLN. INFO.:			US 2003-448114P	P 20030220
			US 2003-508860P	P 20031007
			US 2004-781928	A2 20040220

OTHER SOURCE(S): MARPAT 142:134621  
GI




AB The title compds. I [wherein R1, R2 = H, (cyclo)alkyl, (hetero)aryl, etc.; R3, R4 = H, halo, (un)substituted (cyclo)alkyl, (hetero)aryl, etc.; R5 = H, halo, (un)substituted (hetero)aryl; wherein at least one of R4 and R5 = (hetero)aryl; R6 = H; or pharmaceutically acceptable salts and produgs thereof] were prepared as protein kinase (PK) inhibitors. For example, amination of 3,5-dibromimidazo[1,2-a]pyrazine with methylamine in THF afforded (3-bromimidazo[1,2-a]pyrazin-8-yl)methylamine (50%), which was coupled with phenylboronic acid in THF to give II (63%). Various assays which may be used to determine the level of activity of compds. I against one or more PKs (such as GST-Flk1 receptor tyrosine kinase, fibroblast growth factor type 1 receptors (FGFR1), and platelet-derived growth factor (PDGF) receptors) were described in detail (no data given). Thus, I and pharmaceutical compns. comprising these compds. are useful for treating

disorders related to abnormal PK activity, such as cancer, diabetes, autoimmune disorders, inflammatory disorders, and cardiovascular disorders (no data).

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2004:934327 CAPLUS  
DOCUMENT NUMBER: 141:395578  
TITLE: Preparation of aryl-substituted 8-aminoarylimidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer and other conditions  
INVENTOR(S): Sun, Connie Li; Liang, Congxin; Huang, Ping; Harris, G. Davis; Guan, Huiping  
PATENT ASSIGNEE(S): Sugan, Inc., USA  
SOURCE: U.S. Pat. Appl. Publ., 76 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004220189	A1	20041104	US 2004-781928	20040220
US 2005009832	A1	20050113	US 2004-845586	20040514
PRIORITY APPLN. INFO.:			US 2003-448114P	P 20030220
			US 2003-508860P	P 20031007
			US 2004-781928	A2 20040220

OTHER SOURCE(S): MARPAT 141:395578  
GI



AB Title compds. I [wherein R1, R2 = independently H, acyl, carbamoyl, alkoxy, (un)substituted (cyclo)alkyl, (hetero)aryl, etc.; R3, R4 = independently H, halo, OH, acyl, carbamoyl, alkoxy, sulfamoyl, CN, NO2, NH2, (un)substituted (cyclo)alkyl, (hetero)aryl, etc.; R5 = H, halo, (un)substituted aryl; wherein at least one of R3, R4, and R5 = aryl; R6 = H; or pharmaceutically acceptable salts and produgs thereof] were prepared as protein kinase (PK) inhibitors. For example, amination of 3,5-dibromimidazo[1,2-a]pyrazine with methylamine in THF afforded (3-bromimidazo[1,2-a]pyrazin-8-yl)methylamine (50%), which was coupled with phenylboronic acid in THF to give II (63%). Nine exemplified compds. were tested and found active against GST-Flk1 receptor tyrosine kinase, fibroblast growth factor type 1 receptors (FGFR1), and platelet-derived growth factor (PDGF) receptors (no data). Thus, I and pharmaceutical compns. comprising these compds. are useful for treating disorders related to abnormal PK activity, such as cancer, diabetes, autoimmune disorders, inflammatory disorders, and cardiovascular disorders (no data).

-- file reg

COST IN U.S. DOLLARS  
FULL ESTIMATED COST  
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)  
CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 11:43:47 ON 02 MAR 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 MAR 2006 HIGHEST RN 875609-25-9  
DICTIONARY FILE UPDATES: 1 MAR 2006 HIGHEST RN 875609-25-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TS/CA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
\* The CA roles and document type information have been removed from \*  
\* the IDB default display format and the RD field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

-- s 12 \*\*\* full  
FULL SEARCH INITIATED 11:43:53 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 8444 TO ITERATE

100.0% PROCESSED 8444 ITERATIONS 186 ANSWERS  
SEARCH TIME: 00.00.01

L5 186 SEA SSS FUL L1

-- file caplus  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST  
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)  
CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 11:43:57 ON 02 MAR 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Mar 2006 VOL 144 ISS 10  
FILE LAST UPDATED: 1 Mar 2006 (20060301/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.  
They are available for your review at:

<http://www.cas.org/infopolicy.html>

-- s 15  
L6 2 L5  
-- d 1-2

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:134601 CAPLUS  
DN 142:134621  
TI Preparation of aryl-substituted 8-aminoarylimidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer and other conditions  
IN Sun, Connie Li; Liang, Congxin; Huang, Ping; Harris, G. Davis; Guan, Huiping  
PA Sugan, Inc., USA  
SO U.S. Pat. Appl. Publ., 119 pp., Cont.-in-part of U.S. Ser. No. 781,928.  
CODEN: USXXCO  
DT Patent  
LA English  
FAM.CNT 2  
PATENT NO. KIND DATE APPLICATION NO. DATE  
PI US 2005009832 A1 20050113 US 2004-845586 20040514  
PRAI US 2004220189 A1 20041104 US 2004-781928 20040220  
PRAI US 2003-448114P P 20030220  
US 2003-508860P P 20031007  
US 2004-781928 A2 20040220  
OS MARPAT 142:134621


L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:934327 CAPLUS  
DN 141:395578  
TI Preparation of aryl-substituted 8-aminoarylimidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer and other conditions  
IN Sun, Connie Li; Liang, Congxin; Huang, Ping; Harris, G. Davis; Guan, Huiping  
PA Sugan, Inc., USA  
SO U.S. Pat. Appl. Publ., 76 pp.  
CODEN: USXXCO  
DT Patent  
LA English  
FAM.CNT 2  
PATENT NO. KIND DATE APPLICATION NO. DATE  
PI US 2004220189 A1 20041104 US 2004-781928 20040220

APPLICANTS

US 2005009832 A1 20050113 US 2004-845586 20040514  
PRAI US 2003-448114P P 20030220  
US 2003-508860P P 20031007  
US 2004-781928 A2 20040220  
OS MARPAT 141:395578

-- d 1-2 abs hitstr


L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN  
OI




AB The title compds. I [wherein R1, R2 = H, (cyclo)alkyl, (hetero)aryl, etc.; R3, R4 = H, halo, (un)substituted (cyclo)alkyl, (hetero)aryl, etc.; R5 = H, halo, (un)substituted (hetero)aryl; wherein at least one of R4 and R5 = (hetero)aryl; R6 = H; or pharmaceutically acceptable salts and prodrugs thereof] were prepared as protein kinase (PK) inhibitors. For example, amination of 3,5-dibromoimidazo[1,2-a]pyrazine with methylamine in THP afforded (3-bromoimidazo[1,2-a]pyrazin-8-yl)methylamine (50%), which was coupled with phenylboronic acid in THP to give II (63%). Various assays which may be used to determine the level of activity of compds. I against one or more PKs (such as GSK-3 $\beta$  receptor tyrosine kinase, fibroblast growth factor type 1 receptors (FGFR1), and platelet-derived growth factor (PDGF) receptors) were described in detail (no data given). Thus, I and pharmaceutical compns. comprising these compds. are useful for treating disorders related to abnormal PK activity, such as cancer, diabetes, autoimmune disorders, inflammatory disorders, and cardiovascular disorders (no data).

IT 787590-47-OP, (3-Phenylimidazo[1,2-a]pyrazin-8-yl)amine  
787590-48-1P, (3-(4-Aminophenyl)imidazo[1,2-a]pyrazin-8-yl)amine  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USBS (Uses)  
(Kinase inhibitor; preparation of imidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer and other conditions)


RN 787590-47-0 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-phenyl- (9CI) (CA INDEX NAME)




RN 787590-48-1 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(4-aminophenyl)- (9CI) (CA INDEX NAME)




IT 787590-46-9P, Methyl (3-phenylimidazo[1,2-a]pyrazin-8-yl)amine  
787590-49-2P, N-[4-{[4-(trifluoromethyl)benzoyl]amino}imidazo[1,2-a]pyrazin-3-yl}phenyl]-3-(2-morpholin-4-yl)propyl]urea  
N-[4-(8-Aminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-4-trifluoromethylbenzamide  
787590-52-7P, (4-Methoxyphenyl) (3-phenylimidazo[1,2-a]pyrazin-8-yl)amine  
787590-53-8P, 4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenol  
787590-57-2P, Isopropyl (3-phenylimidazo[1,2-a]pyrazin-8-yl)amine  
787590-59-4P, 4-(8-Isopropylaminoimidazo[1,2-a]pyrazin-3-yl)phenol  
787590-61-8P, Butyl (3-phenylimidazo[1,2-a]pyrazin-8-yl)amine  
787590-63-0P, Ethyl (3-phenylimidazo[1,2-a]pyrazin-8-yl)amine  
787590-65-2P, [2-(Morpholin-4-yl)ethyl] (3-phenylimidazo[1,2-a]pyrazin-8-yl)amine  
787590-67-4P, Benzyl (3-phenylimidazo[1,2-a]pyrazin-8-yl)amine  
787590-69-6P, 2-[[3-Phenylimidazo[1,2-a]pyrazin-8-yl]amino]ethanol  
787590-70-9P, 1-Butyl-3-[(3-phenylimidazo[1,2-a]pyrazin-8-yl)urea]  
787590-71-0P, N-[3-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]acetamide  
787590-72-1P, N-[4-{[8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl}acetamide  
787590-73-2P, 2,6-Dimethyl-4-(8-methylaminoimidazo[1,2-a]pyrazin-3-yl)phenol  
787590-74-3P, [3-(4-Fluorophenyl)imidazo[1,2-a]pyrazin-8-yl]amine  
787590-75-4P, Cyclopropyl (3-phenylimidazo[1,2-a]pyrazin-8-yl)amine  
787590-76-5P, N-[3-(4-Fluorophenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine  
787590-77-6P, Methyl [3-(2-trifluoromethylphenyl)imidazo[1,2-a]pyrazin-8-yl]amine  
787590-78-7P, Methyl [3-(3-trifluoromethylphenyl)imidazo[1,2-a]pyrazin-8-yl]amine  
787590-79-8P, Methyl [3-(2-phenoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]amine  
787590-80-1P, N-[3-(Biphenyl-2-yl)imidazo[1,2-a]pyrazin-8-yl]methylamine  
787590-81-2P, N-[3-(2-Benzoyloxyphenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine  
787590-82-3P, 1-[4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]ethanone  
787590-83-4P, 1-[3-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]ethanone  
787590-84-5P, N-[3-(3-Isopropylphenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine  
787590-85-6P, N-[3-(4-tert-Butylphenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine  
787590-86-7P, N-[3-(4-Cyclohexylphenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine  
787590-87-8P, N-[3-(3,5-Bis(trifluoromethyl)phenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine  
787590-89-0P, 3-(4-Methylaminoimidazo[1,2-a]pyrazin-3-yl)benzoic acid  
787590-91-4P, 4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)benzoic acid  
787590-92-5P, 787590-93-6P, 4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]carbamic acid benzyl ester  
787590-94-7P, Methyl [3-(4-trifluoromethylphenyl)imidazo[1,2-a]pyrazin-8-yl]amine  
787590-95-8P, N-[3-(2,4-Difluorophenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine  
787590-96-9P, N-[3-(3,4-Dichlorophenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine  
787590-98-1P, N-[3-(3-Fluoro-4-methoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine  
787590-99-2P, N-[3-(Biphenyl-4-yl)imidazo[1,2-a]pyrazin-8-yl]methylamine  
787591-00-8P, N-[3-(Biphenyl-3-yl)imidazo[1,2-a]pyrazin-8-yl]methylamine  
787591-01-9P, N-[3-(4-Benzoyloxyphenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine  
787591-02-0P, Methyl [3-(naphthalen-1-yl)imidazo[1,2-a]pyrazin-8-yl]amine  
787591-03-1P, N-[3-(2-Chlorophenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine  
787591-04-2P, N-[3-(8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl)phenyl]acetamide  
787591-05-3P, Methyl [3-(2-trifluoromethoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine  
787591-06-4P, Methyl [3-(3-trifluoromethoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]amine  
787591-07-5P, Cyclopropyl [3-(3-(2-morpholin-4-yl)ethoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]amine  
787591-08-6P, 3-(8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl)phenol  
787591-09-7P, Methyl [3-(4-trifluoromethoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]amine  
787591-10-0P, N-[3-(2-Fluorophenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine  
787591-11-1P, Fluorophenyl [3-(3-(2-morpholin-4-yl)ethoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine  
787591-12-2P, N-[3-(Benzodioxol-5-yl)imidazo[1,2-a]pyrazin-8-yl]methylamine  
787591-13-3P, N-[3-(3-Chlorophenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine  
787591-14-4P, N-[3-(4-Methoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine  
787591-15-5P, N-[3-(2-Methoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine  
787591-16-6P, Methyl [3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]amine  
787591-17-7P, N-[3-(4-Benzoyloxy-3-fluorophenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine  
787591-18-8P, N-[3-(4-Isopropylphenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine  
787591-19-9P, N-[3-(3,5-Bis(trifluoromethyl)phenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine  
787591-20-0P, Cyclopropyl [3-(4-dichlorophenyl)imidazo[1,2-a]pyrazin-8-yl]amine  
787591-21-1P, 3-(8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl)benzoic acid  
787591-22-4P, Methyl [3-(4-(2-morpholin-4-yl)ethoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]amine  
787591-23-5P, Cyclopropyl [3-(4-(2-morpholin-4-yl)ethoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]amine  
787591-24-6P, Cyclopropyl [3-(4-dimethylaminophenyl)imidazo[1,2-a]pyrazin-8-yl]amine  
787591-25-7P, Cyclopropyl [3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]amine  
787591-26-8P, 1-[4-(8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl)phenyl]ethanone  
787591-27-9P, [4-(8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl)phenyl]carbamic acid benzyl ester  
787591-28-0P, N-[4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]acetamide  
787591-29-1P, N-[3-(3-Aminophenyl)imidazo[1,2-a]pyrazin-8-yl] (cyclopropyl)amine  
787591-30-4P, N-[3-(4-Aminophenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine  
787591-31-5P, Methyl [3-(naphthalen-2-yl)imidazo[1,2-a]pyrazin-8-yl]amine  
787591-32-6P, 4-(8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl)benzoic acid  
787591-33-7P, N-[3-(4-Aminophenyl)imidazo[1,2-a]pyrazin-8-yl] (cyclopropyl)amine  
787591-34-8P, Methyl [3-(3-(2-morpholin-4-yl)ethoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]amine  
787591-35-9P, N-[3-(3-Aminophenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine  
787591-37-1P, 3-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenol  
787591-38-2P, 4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)-N-[2-(morpholin-4-yl)ethyl]benzamide  
787591-40-6P, 4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)-N-[3-(morpholin-4-yl)propyl]benzamide  
787591-41-7P, 4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide  
787591-42-8P, 4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-3-(3-(morpholin-4-yl)propyl)urea  
787591-45-1P, 787591-46-2P, 787591-47-3P, 787591-48-4P, 1-[4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[3-(morpholin-4-yl)propyl]urea  
787591-49-5P, 787591-50-6P, 787591-51-7P, 1-[4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[3-(pyrrolidin-1-yl)propyl]urea  
787591-52-8P, 4-(Pyrrolidin-1-yl)piperidine-1-carboxylic acid N-[4-(8-methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]amide  
787591-54-2P, 1-[4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[2-(morpholin-4-yl)ethyl]urea  
787591-56-4P, 4-Hydroxypiperidine-1-carboxylic acid N-[4-(8-methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]amide  
787591-57-5P, 4-Hydroxypiperidine-1-carboxylic acid N-[3-(8-methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]amide  
787591-58-6P, 1-[3-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[2-(morpholin-4-yl)ethyl]urea  
787591-59-7P, 1-[3-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[2-(pyrrolidin-1-yl)ethyl]urea  
787591-61-1P, 1-[3-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[2-(pyrrolidin-1-yl)ethyl]urea  
787591-62-2P, 1-[3-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[2-(pyrrolidin-1-yl)ethyl]urea  
787591-63-3P, 787591-64-5P, 787591-66-6P, 1-[4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[2-(pyrrolidin-1-yl)ethyl]urea  
787591-68-8P, 787591-70-2P, 1-[4-(8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[3-(pyrrolidin-1-yl)propyl]urea  
787591-72-4P, 1-[4-(8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[3-(morpholin-4-yl)propyl]urea  
787591-74-6P, 1-[4-(8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[2-(pyrrolidin-1-yl)ethyl]urea  
787591-75-7P, 1-[4-(8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[2-(morpholin-4-yl)ethyl]urea  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USBS (Uses)  
(Kinase inhibitor; preparation of imidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer and other conditions)



RN 787590-49-2 CAPLUS  
CN Benzamide, 4-(trifluoromethyl)-N-[4-{[4-(trifluoromethyl)benzoyl]amino}imidazo[1,2-a]pyrazin-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 787590-50-5 CAPLUS  
CN Benzamide, N-[4-(8-aminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




ALL APPLICANTS' COMPOUNDS ARE DISPLAYED OVER THE NEXT FEW PAGES


RN 787590-52-7 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-(4-methoxyphenyl)-3-phenyl- (9CI) (CA INDEX NAME)




RN 787590-53-8 CAPLUS  
CN Phenol, 4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]- (9CI) (CA INDEX NAME)




RN 787590-57-2 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-(1-methylethyl)-3-phenyl- (9CI) (CA INDEX NAME)




RN 787590-59-4 CAPLUS  
CN Urea, N-butyl-N'-(3-phenylethylamino)imidazo[1,2-a]pyrazin-3-yl- (9CI) (CA INDEX NAME)




RN 787590-61-8 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-butyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 787590-63-0 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-ethyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 787590-65-2 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-[2-(4-morpholinyl)ethyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 787590-67-4 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 787590-69-6 CAPLUS  
CN Ethanol, 2-[(3-phenylimidazo[1,2-a]pyrazin-8-yl)amino]- (9CI) (CA INDEX NAME)




RN 787590-70-9 CAPLUS  
CN Urea, N-butyl-N'-(3-phenylimidazo[1,2-a]pyrazin-8-yl)- (9CI) (CA INDEX NAME)




RN 787590-71-0 CAPLUS  
CN Acetamide, N-[3-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 787590-72-1 CAPLUS  
CN Acetamide, N-[4-[8-(cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 787590-73-2 CAPLUS  
CN Phenol, 2,6-dimethyl-4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]- (9CI) (CA INDEX NAME)




RN 787590-74-3 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 787590-75-4 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-cyclopropyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 787590-76-5 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(4-fluorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 787590-77-6 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 787590-76-7 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 787590-79-8 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-(2-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 787590-80-1 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-[1,1'-biphenyl]-2-yl-N-methyl- (9CI) (CA INDEX NAME)




RN 787590-81-2 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-[2-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 787590-82-3 CAPLUS  
CN Ethanone, 1-[4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 787590-83-4 CAPLUS  
CN Ethanone, 1-[3-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 787590-84-5 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-[3-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 787590-85-6 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-[4-(1,1-dimethylethyl)phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 787590-86-7 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(4-cyclohexylphenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 787590-87-8 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-[3,5-bis(trifluoromethyl)phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 787590-89-0 CAPLUS  
CN Benzoic acid, 3-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]- (9CI) (CA INDEX NAME)




RN 787590-91-4 CAPLUS  
CN Benzoic acid, 4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]- (9CI) (CA INDEX NAME)



RN 787590-92-5 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 787590-93-6 CAPLUS  
CN Carbanic acid, [4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 787590-94-7 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


(9CI) (CA INDEX NAME)




RN 787590-95-8 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(2,4-difluorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 787590-96-9 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(3,4-dichlorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 787590-98-1 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-[3-fluoro-4-methoxyphenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 787590-99-2 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-[1,1'-biphenyl]-4-yl-N-methyl- (9CI) (CA INDEX NAME)



RN 787591-00-8 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-[(1,1'-biphenyl)-3-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 787591-01-9 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 787591-02-0 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-(1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 787591-03-1 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(2-chlorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 787591-04-2 CAPLUS  
CN Acetamide, N-[3-[8-(cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 787591-05-3 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-[2-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 787591-06-4 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 787591-07-5 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-cyclopropyl-3-[3-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 787591-08-6 CAPLUS  
CN Phenol, 3-[8-(cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]- (9CI) (CA INDEX NAME)




RN 787591-09-7 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 787591-10-0 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(2-fluorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 787591-11-1 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(3,4-difluorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 787591-12-2 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(1,3-benzodioxol-5-yl)-N-methyl- (9CI) (CA INDEX NAME)




RN 787591-13-3 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(3-chlorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 787591-14-4 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(4-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 787591-15-5 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(2-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 787591-16-6 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 787591-17-7 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-[3-fluoro-4-(phenylmethoxy)phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 787591-18-8 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-[4-(1-methylethyl)phenyl]- (9CI)  
(CA INDEX NAME)




RN 787591-19-9 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-[3,5-bis(trifluoromethyl)phenyl]-N-cyclopropyl- (9CI) (CA INDEX NAME)




RN 787591-20-2 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-cyclopropyl-3-(3,4-dichlorophenyl)- (9CI)  
(CA INDEX NAME)




RN 787591-21-3 CAPLUS  
CN Benzoic acid, 3-[8-(cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]- (9CI)  
(CA INDEX NAME)




RN 787591-22-4 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-[4-(2-(4-morpholinyl)ethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 787591-23-5 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-cyclopropyl-3-[4-(2-(4-morpholinyl)ethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 787591-24-6 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-cyclopropyl-3-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 787591-25-7 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-cyclopropyl-3-(4-phenoxyphenyl)- (9CI)  
(CA INDEX NAME)




RN 787591-26-8 CAPLUS  
CN Ethanone, 1-[4-[8-(cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 787591-27-9 CAPLUS  
CN Carbamic acid, [4-[8-(cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 787591-28-0 CAPLUS  
CN Acetamide, N-[4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]- (9CI)  
(CA INDEX NAME)




RN 787591-29-1 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(3-aminophenyl)-N-cyclopropyl- (9CI) (CA INDEX NAME)




RN 787591-30-4 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(4-aminophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 787591-31-5 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-(2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 787591-32-6 CAPLUS  
CN Benzoic acid, 4-[8-(cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]- (9CI)  
(CA INDEX NAME)




RN 787591-33-7 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(4-aminophenyl)-N-cyclopropyl- (9CI) (CA INDEX NAME)




RN 787591-34-6 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amino, N-methyl-3-[3-(4-morpholinyl)ethoxyphenyl]- (9CI) (CA INDEX NAME)




RN 787591-36-0 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(3-aminophenyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 787591-37-1 CAPLUS  
CN Phenol, 3-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]- (9CI) (CA INDEX NAME)




RN 787591-38-2 CAPLUS  
CN Benzamide, 4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 787591-40-6 CAPLUS


CN Benzamide, 4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 787591-41-7 CAPLUS  
CN Benzamide, 4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 787591-42-8 CAPLUS  
CN Urea, N-[3-(8-(methylamino)imidazo[1,2-a]pyrazin-3-yl)phenyl]-N'-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)




RN 787591-45-1 CAPLUS  
CN 1-Pyrrolidinecarboxamide, N-[4-[8-(cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-2-(1-pyrrolidinylmethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 787591-46-2 CAPLUS  
CN 1-Pyrrolidinecarboxamide, N-[4-[8-(cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-2-(1-pyrrolidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 787591-47-3 CAPLUS  
CN 1-Pyrrolidinecarboxamide, N-[4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-2-(1-pyrrolidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 787591-48-4 CAPLUS  
CN Urea, N-[4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-N'-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)




RN 787591-49-5 CAPLUS  
CN 1-Pyrrolidinecarboxamide, 3-hydroxy-N-[4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 787591-50-8 CAPLUS  
CN 1-Pyrrolidinecarboxamide, N-[3-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-2-(1-pyrrolidinylmethyl)-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787591-51-9 CAPLUS  
CN Urea, N-[4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-N'-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 787591-52-0 CAPLUS  
CN 1-Piperidinecarboxamide, N-[4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 787591-54-2 CAPLUS  
CN Urea, N-[4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-N'-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)







RN 787591-56-4 CAPLUS  
CN 1-Piperidinecarboxamide, 4-hydroxy-N-[4-[(8-methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 787591-57-5 CAPLUS  
CN 1-Piperidinecarboxamide, 4-hydroxy-N-[3-[(8-methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 787591-58-6 CAPLUS  
CN Urea, N-[3-[(8-methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-N'-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 787591-59-7 CAPLUS  
CN Urea, N-[3-[(8-methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-N'-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 787591-61-1 CAPLUS  
CN Urea, N-[3-[(8-methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-N'-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 787591-63-3 CAPLUS  
CN 1-Pyrrolidinecarboxamide, N-[4-[(8-methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-2-(1-pyrrolidinylmethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 787591-65-5 CAPLUS  
CN 1-Pyrrolidinecarboxamide, 2-[(dimethylamino)methyl]-N-[4-[(8-methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 787591-66-6 CAPLUS  
CN Urea, N-[4-[(8-methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-N'-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 787591-68-8 CAPLUS  
CN 1-Pyrrolidinecarboxamide, 3-hydroxy-N-[4-[(8-methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]- (9CI) (CA INDEX NAME)

a]pyrazin-3-yl]phenyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 787591-70-2 CAPLUS  
CN Urea, N-[4-[(8-(cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-N'-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 787591-72-4 CAPLUS  
CN Urea, N-[4-[(8-(cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-N'-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)




RN 787591-74-6 CAPLUS  
CN Urea, N-[4-[(8-(cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-N'-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 787591-75-7 CAPLUS  
CN Urea, N-[4-[(8-(cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-N'-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



IT 825630-53-3P 825630-65-7P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(Preparation of imidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer and other conditions)  
RN 825630-53-3 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-[(1H-indol-5-yl)-N-methyl]- (9CI) (CA INDEX NAME)



RN 825630-65-7 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-[(1H-indol-5-yl)-N-methyl]- (9CI) (CA INDEX NAME)




IT 825629-70-7P 825629-71-8P 825629-72-9P  
825629-73-0P 825629-74-1P 825629-75-2P  
825629-76-3P 825629-77-4P 825629-78-5P  
825629-79-6P 825629-80-9P 825629-81-0P  
825629-82-1P 825629-83-2P 825629-84-3P  
825629-85-4P 825629-86-5P 825629-87-6P  
825629-88-7P 825629-89-8P 825629-90-1P  
825629-91-2P 825629-92-3P 825629-93-4P  
825629-94-5P 825629-95-6P 825629-96-7P  
825629-97-8P 825629-98-9P 825629-99-0P  
825630-00-0P 825630-01-1P 825630-02-2P  
825630-03-3P 825630-04-4P 825630-05-5P  
825630-06-6P 825630-07-7P 825630-08-8P  
825630-09-9P 825630-10-2P 825630-11-3P  
825630-12-4P 825630-13-5P 825630-14-6P

825630-15-7P 825630-16-6P 825630-17-9P  
825630-18-0P 825630-19-1P 825630-20-4P  
825630-21-5P 825630-22-6P 825630-23-7P  
825630-24-8P 825630-25-9P 825630-26-0P  
825630-27-1P 825630-28-2P 825630-29-3P  
825630-30-6P 825630-31-7P 825630-32-8P  
825630-33-9P 825630-34-0P 825630-35-1P  
825630-36-2P 825630-37-3P 825630-38-4P  
825630-39-5P 825630-40-6P 825630-41-7P  
825630-42-8P 825630-43-9P 825630-44-0P  
825630-45-1P 825630-46-2P 825630-47-3P  
825630-48-4P 825630-49-5P 825630-50-6P  
825630-51-7P 825630-52-8P 825630-53-9P  
825630-54-0P 825630-55-1P 825630-56-2P  
825630-57-3P 825630-58-4P 825630-59-5P  
825630-60-6P 825630-61-7P 825630-62-8P  
825630-63-9P 825630-64-0P 825630-65-1P  
825630-66-2P 825630-67-3P 825630-68-4P  
825630-69-5P 825630-70-6P 825630-71-7P  
825630-72-8P 825630-73-9P 825630-74-0P  
825630-75-1P 825630-76-2P 825630-77-3P  
825630-78-4P 825630-79-5P 825630-80-6P  
825630-81-7P 825630-82-8P 825630-83-9P  
825630-84-0P 825630-85-1P 825630-86-2P  
825630-87-3P 825630-88-4P 825630-89-5P  
825630-90-6P 825630-91-7P 825630-92-8P  
825630-93-9P 825630-94-0P 825630-95-1P  
825630-96-2P 825630-97-3P 825630-98-4P  
825630-99-5P 825630-100-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer and other conditions)


RN 825629-70-7 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 825629-71-8 CAPLUS  
CN 4-Morpholineacetamide, N-[4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 825629-72-9 CAPLUS  
CN Acetamide, 2-(diethylamino)-N-[4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 825629-73-0 CAPLUS  
CN Acetamide, N-[4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 825629-74-1 CAPLUS  
CN 1-Piperazineacetamide, 4-methyl-N-[4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 825629-75-2 CAPLUS  
CN 1-Piperidineacetamide, 4-hydroxy-N-[4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 825629-76-3 CAPLUS  
CN Acetamide, N-[3-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 825629-77-4 CAPLUS  
CN 1-Piperazineacetamide, 4-methyl-N-[3-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 825629-78-5 CAPLUS  
CN 4-Morpholineacetamide, N-[3-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 825629-79-6 CAPLUS  
CN 1-Piperidineacetamide, 4-hydroxy-N-[3-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 825629-80-9 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[3-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 825629-81-0 CAPLUS  
CN Acetamide, 2-hydroxy-N-[4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 825629-82-1 CAPLUS  
CN Acetamide, N-[4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-2-(4-morpholinylethoxy)- (9CI) (CA INDEX NAME)



RN 825629-83-2 CAPLUS  
CN Ethanone, 1-[4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-2-(4-morpholinylethoxy)- (9CI) (CA INDEX NAME)




RN 825629-84-3 CAPLUS  
CN Urea, N-[4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-N'-[4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 825629-85-4 CAPLUS  
CN Urea, N-[2-hydroxy-3-(4-morpholinyl)propyl]-N'-[4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-N'-[(2S)-2-phenylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 825629-86-5 CAPLUS  
CN Urea, N-[2-hydroxyethyl]-N'-[4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 825629-87-6 CAPLUS  
CN Urea, N-[4-[8-(cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-N'-[2-hydroxyethyl]- (9CI) (CA INDEX NAME)




RN 825629-88-7 CAPLUS  
CN Urea, N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]-N'-(2-(4-methyl-1-piperazinyl)ethyl)- (9CI) (CA INDEX NAME)




RN 825629-89-8 CAPLUS  
CN Urea, N-[4-(4-chlorophenyl)methyl]-N'-(4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl)- (9CI) (CA INDEX NAME)




RN 825629-90-1 CAPLUS  
CN Urea, N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]-N'-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 825629-91-2 CAPLUS  
CN Urea, N-[4-(2-fluorophenyl)methyl]-N'-(4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl)- (9CI) (CA INDEX NAME)




RN 825629-92-3 CAPLUS




RN 825629-97-8 CAPLUS  
CN Urea, N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]-N'-(4-(4-morpholinyl)phenyl)methyl)- (9CI) (CA INDEX NAME)




RN 825629-98-9 CAPLUS  
CN Urea, N-[4-(4-fluorophenyl)methyl]-N'-(4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl)- (9CI) (CA INDEX NAME)



RN 825629-99-0 CAPLUS  
CN Urea, N-[4-(4-methoxyphenyl)methyl]-N'-(4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl)- (9CI) (CA INDEX NAME)




RN 825630-00-0 CAPLUS  
CN Urea, N-[2-(1,1-dioxido-4-thiomorpholinyl)ethyl]-N'-(4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl)- (9CI) (CA INDEX NAME)




RN 825630-01-1 CAPLUS

CN Urea, N-[2-(4-hydroxyphenyl)ethyl]-N'-(4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl)- (9CI) (CA INDEX NAME)



RN 825629-93-4 CAPLUS  
CN Urea, N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]-N'-(2-{4-(2-morpholinyl)ethoxy}phenyl)ethyl)- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B



RN 825629-94-5 CAPLUS  
CN Urea, N-[4-(4-hydroxyphenyl)methyl]-N'-(4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl)- (9CI) (CA INDEX NAME)




RN 825629-95-6 CAPLUS  
CN Urea, N-[4-(2-fluorophenyl)methyl]-N'-(4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl)- (9CI) (CA INDEX NAME)




RN 825629-96-7 CAPLUS  
CN Urea, N-[4-(4-morpholinyl)phenyl)methyl]-N'-(4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl)- (9CI) (CA INDEX NAME)


CN Benzenemethanol, 4-[8-(cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]- (9CI) (CA INDEX NAME)




RN 825630-02-2 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-[4-[(2-(1-pyrrolidinyl)ethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 825630-03-3 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-[3-[(2-(4-morpholinyl)ethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 825630-04-4 CAPLUS  
CN 1,2-Ethanediame, N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 825630-05-5 CAPLUS  
CN 1-Piperidineethanesulfonamide, N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 825630-06-6 CAPLUS  
CN Ethanesulfonamide, 2-(diethylamino)-N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 825630-07-7 CAPLUS  
CN Ethanesulfonamide, 2-(cyclopropylamino)-N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 825630-08-8 CAPLUS  
CN Methanesulfonamide, N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 825630-09-9 CAPLUS  
CN 2-Oxazolidinone, 3-[[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 825630-10-2 CAPLUS  
CN Morpholine, 4-[[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 825630-11-3 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 825630-12-4 CAPLUS  
CN Ethanone, 1-[4-{8-(cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 825630-13-5 CAPLUS  
CN Benzenemethanol, 4-[8-(cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]-α-methyl- (9CI) (CA INDEX NAME)




RN 825630-14-6 CAPLUS  
CN Ethanethiol, 2-[[[3-chlorophenyl]methyl]amino]-N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 825630-15-7 CAPLUS  
CN Ethanesulfonamide, 2-[[[4-(4-chlorophenyl)methyl]amino]-N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 825630-16-8 CAPLUS  
CN Ethanesulfonamide, 2-[[[2-(2-chlorophenyl)methyl]amino]-N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 825630-17-9 CAPLUS  
CN Urea, N-[(2,6-difluorophenyl)methyl]-N'-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 825630-18-0 CAPLUS  
CN Urea, N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]-N'-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 825630-19-1 CAPLUS  
CN Urea, N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]-N'-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 825630-20-4 CAPLUS  
CN Urea, N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]-N'-(2-(2-pyridinyl)ethyl)- (9CI) (CA INDEX NAME)




RN 825630-21-5 CAPLUS  
CN Acetamide, N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]-2-[(2-phenylcyclopropyl)amino]- (9CI) (CA INDEX NAME)




RN 825630-22-6 CAPLUS  
CN Acetamide, 2-[[[4-(4-chlorophenyl)ethyl]amino]-N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 825630-23-7 CAPLUS  
CN Carbamic acid, [4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]-2-(4-fluorophenyl)propyl ester (9CI) (CA INDEX NAME)




RN 825630-24-8 CAPLUS  
CN Carbamic acid, [4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]-2-(2-chlorophenyl)ethyl ester (9CI) (CA INDEX NAME)




RN 825630-25-9 CAPLUS  
CN Acetamide, N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]-2-phenoxy- (9CI) (CA INDEX NAME)




RN 825630-26-0 CAPLUS  
CN Acetamide, 2-[[2,6-difluorophenyl]methoxy]-N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 825630-27-1 CAPLUS  
CN Acetamide, 2-[2-(2-fluorophenyl)ethoxy]-N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 825630-28-2 CAPLUS  
CN Acetamide, 2-[2-(2,6-difluorophenyl)ethoxy]-N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 825630-29-3 CAPLUS  
CN Urea, N-[(3-hydroxyphenyl)methyl]-N'-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 825630-30-6 CAPLUS  
CN Acetamide, 2-[[2,6-fluorophenyl]methoxy]-N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 825630-31-7 CAPLUS  
CN Acetamide, N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]-2-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 825630-32-8 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-[4-{[1-[(2-(5-chloro-2-fluorophenyl)ethoxy)methyl]ethenyl]amino}phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 825630-33-9 CAPLUS  
CN Urea, N-[(2-chloro-5-fluorophenyl)methyl]-N'-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 825630-34-0 CAPLUS  
CN Urea, N-(2,4-dichlorophenyl)-N'-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 825630-35-1 CAPLUS  
CN Urea, N-(2,3-dihydro-1H-inden-1-yl)-N'-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 825630-36-2 CAPLUS  
CN Urea, N-[2-(2,6-dichlorophenyl)ethyl]-N'-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 825630-52-2 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(1H-indol-4-yl)- (9CI) (CA INDEX NAME)




RN 825630-54-4 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-cyclopropyl-3-(1H-indol-4-yl)- (9CI) (CA INDEX NAME)




RN 825630-55-5 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(1H-indol-4-yl)-N-methyl- (9CI) (CA INDEX NAME)




RN 825630-63-5 CAPLUS  
CN 1H-Indole-3-acetamide, 5-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]- (9CI) (CA INDEX NAME)




RN 825630-66-8 CAPLUS  
CN 1H-Indole-2-carboxamide, 5-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)




RN 825630-67-9 CAPLUS  
CN 1H-Indole-2-carboxamide, 5-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 825630-68-0 CAPLUS  
CN 1H-Indole-2-carboxamide, N-(2-(diethylamino)ethyl)-5-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]- (9CI) (CA INDEX NAME)




RN 825630-69-1 CAPLUS  
CN Morpholine, 4-[[5-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]-1H-indol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 825630-77-1 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-[1-[2-(diethylamino)ethyl]-1H-indol-5-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 825630-78-2 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-[1-[3-(4-morpholinyl)propyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 825631-59-2 CAPLUS  
CN Urea, N-[4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-N'-(2-(3-pyridinyl)ethyl)- (9CI) (CA INDEX NAME)




IT 825630-85-1P 825630-86-2P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of imidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer under other conditions)  
RN 825630-85-1 CAPLUS  
CN 1H-Indole-2-carboxylic acid, 5-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 825630-86-2 CAPLUS  
CN 1H-Indole-2-carboxylic acid, 5-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]- (9CI) (CA INDEX NAME)




L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN  
GI




AB Title compds. I [wherein R1, R2 = independently H, acyl, carbamoyl, alkoxy, (un)substituted (cyclo)alkyl, (hetero)aryl, etc.; R3, R4 = independently H, halo, OH, acyl, carbamoyl, alkoxy, sulfamoyl, CN, NO2, NH2, (un)substituted (cyclo)alkyl, (hetero)aryl, etc.; R5 = H, halo, (un)substituted aryl; wherein at least one of R3, R4, and R5 = aryl; R6 = H, or pharmaceutically acceptable salts and prodrugs thereof] were prepared as protein kinase (PK) inhibitors. For example, amination of 3,5-dibromoimidazo[1,2-a]pyrazine with methylamine in THF afforded (3-bromoimidazo[1,2-a]pyrazin-8-yl)methylamine (50%), which was coupled with phenylboronic acid in THF to give II (63%). Nine exemplified compds. were tested and found active against GSK-3β receptor tyrosine kinase, fibroblast growth factor type 1 receptors (FGFR1), and platelet-derived growth factor (PDGF) receptors (no data). Thus, I and pharmaceutical compds. comprising these compds. are useful for treating disorders related to abnormal PK activity, such as cancer, diabetes, autoimmune disorders, inflammatory disorders, and cardiovascular disorders (no data).

IT 787590-47-OP, (3-Phenylimidazo[1,2-a]pyrazin-8-yl)amine  
787590-48-1P, (3-(4-Aminophenyl)imidazo[1,2-a]pyrazin-8-yl)amine  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USSS (Uses)  
(Kinase inhibitor; preparation of imidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer and other conditions)

RN 787590-47-0 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-phenyl- (9CI) (CA INDEX NAME)



RN 787590-48-1 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(4-aminophenyl)- (9CI) (CA INDEX NAME)




IT 787590-46-9P, Methyl (3-phenylimidazo[1,2-a]pyrazin-8-yl)amine  
787590-49-2P, N-[4-[8-(4-Trifluoromethylbenzoyl)amino]imidazo[1,2-a]pyrazin-3-yl]phenyl]-4-trifluoromethylbenzamide 787590-50-5P.


N-[4-(8-Aminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-4-trifluoromethylbenzamide  
787590-52-7P, (4-Methoxyphenyl) (3-phenylimidazo[1,2-a]pyrazin-8-yl)amine 787590-53-8P, 4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenol 787590-57-2P, Isopropyl (3-phenylimidazo[1,2-a]pyrazin-8-yl)amine 787590-59-4P, 4-(8-Isopropylaminoimidazo[1,2-a]pyrazin-3-yl)phenol 787590-61-8P, Butyl (3-phenylimidazo[1,2-a]pyrazin-8-yl)amine 787590-63-0P, Ethyl (3-phenylimidazo[1,2-a]pyrazin-8-yl)amine 787590-65-2P, [2-(Morpholin-4-yl)ethyl] (3-phenylimidazo[1,2-a]pyrazin-8-yl)amine 787590-67-4P, Benzyl (3-phenylimidazo[1,2-a]pyrazin-8-yl)amine 787590-69-6P, 2-[[3-Phenylimidazo[1,2-a]pyrazin-8-yl]amino]ethanol 787590-70-9P, 1-Butyl-3-(3-phenylimidazo[1,2-a]pyrazin-8-yl)urea 787590-71-0P, N-[3-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]acetamide 787590-72-1P, N-[4-(8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl)phenyl]acetamide 787590-73-2P, 2,6-Dimethyl-4-(8-methylaminoimidazo[1,2-a]pyrazin-3-yl)phenol 787590-74-3P, [3-(4-Fluorophenyl)imidazo[1,2-a]pyrazin-8-yl]amine 787590-75-4P, Cyclopropyl (3-phenylimidazo[1,2-a]pyrazin-8-yl)amine 787590-76-5P, N-[3-(4-Fluorophenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine 787590-77-6P, Methyl [3-(2-trifluoromethylphenyl)imidazo[1,2-a]pyrazin-8-yl]amine 787590-78-7P, Methyl [3-(3-trifluoromethylphenyl)imidazo[1,2-a]pyrazin-8-yl]amine 787590-79-8P, Methyl [3-(2-phenoxypheyl)imidazo[1,2-a]pyrazin-8-yl]amine 787590-80-1P, N-[3-(Biphenyl-2-yl)imidazo[1,2-a]pyrazin-8-yl]methylamine 787590-81-2P, N-[3-(2-Benzoyloxyphenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine 787590-82-3P, 1-[4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]ethanone 787590-83-4P, 1-[3-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]ethanone 787590-84-5P, N-[3-(3-Isopropylphenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine 787590-85-6P, N-[3-(4-tert-Butylphenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine 787590-86-7P, N-[3-(4-Cyclohexylphenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine 787590-87-8P, N-[3-(3,5-Bis(trifluoromethyl)phenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine 787590-89-0P, 3-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)benzoic acid 787590-91-4P, 4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)benzoic acid 787590-92-5P 787590-93-6P, 4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]carbamate benzyl ester 787590-94-7P, Methyl [3-(4-trifluoromethylphenyl)imidazo[1,2-a]pyrazin-8-yl]amine 787590-95-8P, N-[3-(2,4-Difluorophenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine 787590-96-9P, N-[3-(3,4-Dichlorophenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine 787590-98-1P, N-[3-(3-Fluoro-4-methoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine 787590-99-2P, N-[3-(Biphenyl-4-yl)imidazo[1,2-a]pyrazin-8-yl]methylamine 787591-00-8P, N-[3-(Biphenyl-3-yl)imidazo[1,2-a]pyrazin-8-yl]methylamine 787591-01-9P, N-[3-(4-Benzoyloxyphenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine 787591-02-0P, Methyl [3-(naphthalen-1-yl)imidazo[1,2-a]pyrazin-8-yl]amine 787591-03-1P, N-[3-(2-Chlorophenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine 787591-04-2P, N-[3-(8-Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]acetamide 787591-05-3P, Methyl [3-(2-trifluoromethoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]amine 787591-06-4P, Methyl [3-(3-trifluoromethoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]amine 787591-07-5P, Cyclopropyl [3-(3-(2-morpholin-4-yl)ethoxy)phenyl]imidazo[1,2-a]pyrazin-8-yl]amine 787591-08-6P, 3-[8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenol 787591-09-7P, Methyl [3-(4-trifluoromethoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]amine 787591-10-0P, N-[3-(2-Fluorophenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine 787591-11-1P, N-[3-(3,4-Difluorophenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine 787591-12-2P, N-[3-(Benzodioxol-5-yl)imidazo[1,2-a]pyrazin-8-yl]methylamine 787591-13-3P, N-[3-(3-Chlorophenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine 787591-14-4P, N-[3-(4-

Methoxyphenyl)imidazo[1,2-a]pyrazin-8-yl)methylamine 787591-15-5P  
 N-[3-(2-Methoxyphenyl)imidazo[1,2-a]pyrazin-6-yl)methylamine  
 787591-16-6P, Methyl[3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]amine 787591-17-7P, N-[3-(4-Benzyloxy-3-fluorophenyl)imidazo[1,2-a]pyrazin-8-yl)methylamine 787591-18-8P  
 N-[3-(4-Isopropylphenyl)imidazo[1,2-a]pyrazin-8-yl)methylamine 787591-19-9P, N-[3-[3,5-Bis(trifluoromethyl)phenyl]imidazo[1,2-a]pyrazin-8-yl](cyclopropyl)amine 787591-20-2P, Cyclopropyl[3-(3,4-dichlorophenyl)imidazo[1,2-a]pyrazin-8-yl]amine 787591-21-3P, 3-[8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]benzoic acid 787591-22-4P, Methyl[3-[4-[2-(morpholin-4-yl)ethoxy]phenyl]imidazo[1,2-a]pyrazin-8-yl]amine 787591-23-5P, Cyclopropyl[3-[4-[2-(morpholin-4-yl)ethoxy]phenyl]imidazo[1,2-a]pyrazin-8-yl]amine 787591-24-6P, Cyclopropyl[3-(4-dimethylaminophenyl)imidazo[1,2-a]pyrazin-8-yl]amine 787591-25-7P, Cyclopropyl[3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]amine 787591-26-8P, 1-[4-[8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]ethanone 787591-27-9P, 1-[4-[8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]carbamic acid benzyl ester 787591-28-0P, N-[4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]acetamide 787591-29-1P, N-[3-(3-Aminophenyl)imidazo[1,2-a]pyrazin-8-yl](cyclopropyl)amine 787591-30-4P, N-[3-(4-Aminophenyl)imidazo[1,2-a]pyrazin-8-yl)methylamine 787591-31-5P, Methyl[3-(naphthalen-2-yl)imidazo[1,2-a]pyrazin-8-yl]amine 787591-32-6P, 4-[8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]benzoic acid 787591-33-7P, N-[3-(4-Aminophenyl)imidazo[1,2-a]pyrazin-8-yl](cyclopropyl)amine 787591-34-8P, Methyl[3-[2-(morpholin-4-yl)ethoxy]phenyl]imidazo[1,2-a]pyrazin-8-yl]amine 787591-36-0P, N-[3-(3-Aminophenyl)imidazo[1,2-a]pyrazin-8-yl)methylamine 787591-37-1P, 3-[8-Methylaminoimidazo[1,2-a]pyrazin-3-yl]phenol 787591-38-2P, 4-[8-Methylaminoimidazo[1,2-a]pyrazin-3-yl]-N-[2-(morpholin-4-yl)ethyl]benzamide 787591-40-6P, 4-[8-Methylaminoimidazo[1,2-a]pyrazin-3-yl]-N-[3-(morpholin-4-yl)propyl]benzamide 787591-41-7P, 4-[8-Methylaminoimidazo[1,2-a]pyrazin-3-yl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide 787591-42-8P, 1-[3-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[3-(morpholin-4-yl)propyl]urea 787591-45-1P, 787591-46-2P 787591-47-3P 787591-48-4P, 1-[4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[3-(morpholin-4-yl)propyl]urea 787591-49-5P 787591-50-6P, 787591-51-9P, 1-[4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[3-(pyrrolidin-1-yl)propyl]urea 787591-52-0P, 4-(Pyrrolidin-1-yl)piperidine-1-carboxylic acid N-[4-(8-methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]amide 787591-54-2P, 1-[4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[2-(morpholin-4-yl)ethyl]urea 787591-56-4P, 4-Hydroxypiperidine-1-carboxylic acid N-[4-(8-methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]amide 787591-57-5P, 4-Hydroxypiperidine-1-carboxylic acid N-[3-(8-methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]amide 787591-58-6P, 1-[3-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[2-(morpholin-4-yl)ethyl]urea 787591-59-7P, 1-[3-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[2-(pyrrolidin-1-yl)ethyl]urea 787591-61-1P, 1-[3-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[3-(pyrrolidin-1-yl)propyl]urea 787591-63-3P 787591-65-5P 787591-66-6P, 1-[4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[2-(pyrrolidin-1-yl)ethyl]urea 787591-68-8P 787591-70-2P, 1-[4-(8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[3-(pyrrolidin-1-yl)propyl]urea 787591-72-4P, 1-[4-[8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-3-[3-(morpholin-4-yl)propyl]urea 787591-74-6P, 1-[4-[8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-3-[2-(pyrrolidin-1-yl)ethyl]urea 787591-75-7P, 1-[4-[8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-3-[2-(morpholin-4-


yl)ethyl]urea  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (kinase inhibitor; preparation of imidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer and other conditions)  
 RN 787590-46-9 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 787590-49-2 CAPLUS  
 CN Benzamide, 4-(trifluoromethyl)-N-[4-[8-[[4-(trifluoromethyl)benzoyl]amino]imidazo[1,2-a]pyrazin-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 787590-50-5 CAPLUS  
 CN Benzamide, N-[4-(8-aminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 787590-52-7 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-8-amine, N-(4-methoxyphenyl)-3-phenyl- (9CI) (CA INDEX NAME)




RN 787590-53-8 CAPLUS  
 CN Phenol, 4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]- (9CI) (CA INDEX NAME)




RN 787590-57-2 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-8-amine, N-(1-methylethyl)-3-phenyl- (9CI) (CA INDEX NAME)




RN 787590-59-4 CAPLUS  
 CN Phenol, 4-[8-[(1-methylethyl)amino]imidazo[1,2-a]pyrazin-3-yl]- (9CI) (CA INDEX NAME)




RN 787590-61-8 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-8-amine, N-butyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 787590-63-0 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-8-amine, N-ethyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 787590-65-2 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-8-amine, N-[2-(4-morpholinyl)ethyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 787590-67-4 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-8-amine, 3-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 787590-69-6 CAPLUS  
 CN Ethanol, 2-[(3-phenylimidazo[1,2-a]pyrazin-8-yl)amino]- (9CI) (CA INDEX NAME)




RN 787590-70-9 CAPLUS  
CN Urea, N-butyl-N'-(3-phenylimidazo[1,2-a]pyrazin-8-yl)- (9CI) (CA INDEX NAME)




RN 787590-71-0 CAPLUS  
CN Acetamide, N-[3-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 787590-72-1 CAPLUS  
CN Acetamide, N-[4-[8-(cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 787590-73-2 CAPLUS  
CN Phenol, 2,6-dimethyl-4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]- (9CI) (CA INDEX NAME)




RN 787590-74-3 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 787590-75-4 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-cyclopropyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 787590-76-5 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(4-fluorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 787590-77-6 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 787590-78-7 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 787590-79-8 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-(2-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 787590-80-1 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-[1,1'-biphenyl]-2-yl-N-methyl- (9CI) (CA INDEX NAME)




RN 787590-81-2 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-[2-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 787590-82-3 CAPLUS  
CN Stenone, 1-[4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 787590-83-4 CAPLUS  
CN Stenone, 1-[3-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 787590-84-5 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-[3-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 787590-85-6 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-[4-(1,1-dimethylethyl)phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 787590-86-7 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(4-cyclohexylphenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 787590-87-8 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-[3,5-bis(trifluoromethyl)phenyl]-N-methyl- (9CI) (CA INDEX NAME)







RN 787590-89-0 CAPLUS  
CN Benzoic acid, 3-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]- (9CI) (CA INDEX NAME)




RN 787590-91-4 CAPLUS  
CN Benzoic acid, 4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]- (9CI) (CA INDEX NAME)



RN 787590-92-5 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 787590-93-6 CAPLUS  
CN Carbamic acid, [4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 787590-94-7 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-[4-(trifluoromethyl)phenyl]-


(9CI) (CA INDEX NAME)




RN 787590-95-8 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(2,4-difluorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 787590-96-9 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(3,4-dichlorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 787590-98-1 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-[3-fluoro-4-methoxyphenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 787590-99-2 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-[1,1'-biphenyl]-4-yl-N-methyl- (9CI) (CA INDEX NAME)




RN 787591-00-8 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-[1,1'-biphenyl]-3-yl-N-methyl- (9CI) (CA INDEX NAME)




RN 787591-01-9 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 787591-02-0 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-(1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 787591-03-1 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(2-chlorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 787591-04-2 CAPLUS  
CN Acetamide, N-[3-[8-(cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 787591-05-3 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-[2-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 787591-06-4 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 787591-07-5 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-cyclopropyl-3-[3-(2-(4-morpholinyl)ethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 787591-08-6 CAPLUS  
CN Phenol, 3-[8-(cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]- (9CI) (CA INDEX NAME)




RN 787591-09-7 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 787591-10-0 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(2-fluorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 787591-11-1 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(3,4-difluorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 787591-12-2 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(1,3-benzodioxol-5-yl)-N-methyl- (9CI) (CA INDEX NAME)




RN 787591-16-8 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 787591-19-9 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-[3,5-bis(trifluoromethyl)phenyl]-N-cyclopropyl- (9CI) (CA INDEX NAME)




RN 787591-20-2 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-cyclopropyl-3-[3,4-dichlorophenyl]- (9CI) (CA INDEX NAME)




RN 787591-21-3 CAPLUS  
CN Benzoic acid, 3-[8-(cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]- (9CI) (CA INDEX NAME)


RN 787591-13-3 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(3-chlorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 787591-14-4 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(4-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 787591-15-5 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(2-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 787591-16-6 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 787591-17-7 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-[3-fluoro-4-(phenylmethoxy)phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 787591-22-4 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-[4-(2-(4-morpholinyl)ethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 787591-23-5 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-cyclopropyl-3-[4-(2-(4-morpholinyl)ethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 787591-24-6 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-cyclopropyl-3-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 787591-25-7 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-cyclopropyl-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 787591-26-8 CAPLUS  
CN Ethanone, 1-[4-{8-(cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 787591-27-9 CAPLUS  
CN Carbamic acid, [4-{8-(cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 787591-28-0 CAPLUS  
CN Acetamide, N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 787591-29-1 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(3-aminophenyl)-N-cyclopropyl- (9CI) (CA INDEX NAME)




RN 787591-30-4 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(4-aminophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 787591-31-5 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-(2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 787591-32-6 CAPLUS  
CN Benzoic acid, 4-[8-(cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]- (9CI) (CA INDEX NAME)




RN 787591-33-7 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(4-aminophenyl)-N-cyclopropyl- (9CI) (CA INDEX NAME)




RN 787591-34-8 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N-methyl-3-[3-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 787591-36-0 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(3-aminophenyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 787591-37-1 CAPLUS  
CN Phenol, 3-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]- (9CI) (CA INDEX NAME)




RN 787591-38-2 CAPLUS  
CN Benzamide, 4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 787591-40-6 CAPLUS


CN Benzamide, 4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 787591-41-7 CAPLUS  
CN Benzamide, 4-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 787591-42-8 CAPLUS  
CN Urea, N-[3-[8-(methylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-N'-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)




RN 787591-45-1 CAPLUS  
CN 1-Pyrrolidinecarboxamide, N-[4-[8-(cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-2-(1-pyrrolidinylmethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 787591-46-2 CAPLUS  
CN 1-Pyrrolidinecarboxamide, N-[4-[8-(cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-2-(1-pyrrolidinylmethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 787591-47-3 CAPLUS  
CN 1-Pyrrolidinecarboxamide, N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]-2-(1-pyrrolidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 787591-48-4 CAPLUS  
CN Urea, N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]-N'-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)




RN 787591-49-5 CAPLUS  
CN 1-Pyrrolidinecarboxamide, 3-hydroxy-N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 787591-50-8 CAPLUS  
CN 1-Pyrrolidinecarboxamide, N-[3-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]-2-(1-pyrrolidinylmethyl)-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 787591-51-9 CAPLUS  
CN Urea, N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]-N'-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 787591-52-0 CAPLUS  
CN 1-Piperidinecarboxamide, N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 787591-54-2 CAPLUS  
CN Urea, N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]-N'-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 787591-56-4 CAPLUS  
CN 1-Piperidinecarboxamide, 4-hydroxy-N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 787591-57-5 CAPLUS  
CN 1-Piperidinecarboxamide, 4-hydroxy-N-[3-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 787591-58-6 CAPLUS  
CN Urea, N-[3-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]-N'-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 787591-59-7 CAPLUS  
CN Urea, N-[3-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]-N'-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 787591-61-1 CAPLUS  
CN Urea, N-[3-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]-N'-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 787591-63-3 CAPLUS  
CN 1-Pyrrolidinecarboxamide, N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]-2-(1-pyrrolidinylmethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 787591-65-5 CAPLUS  
CN 1-Pyrrolidinecarboxamide, 2-[(dimethylamino)methyl]-N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 787591-66-6 CAPLUS  
CN Urea, N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]-N'-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 787591-68-8 CAPLUS  
CN 1-Pyrrolidinecarboxamide, 3-hydroxy-N-[4-{8-(methylamino)imidazo[1,2-a]pyrazin-3-yl}phenyl]- (9CI) (CA INDEX NAME)


alpyrazin-3-yl]phenyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 787591-70-3 CAPLUS

CN Urea, N-[4-[[8-(cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-N'-[3-(1-pyrrolidinyl)propyl]]- (9CI) (CA INDEX NAME)




RN 787591-72-4 CAPLUS

CN Urea, N-[4-[[8-(cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-N'-[3-(4-morpholinyl)propyl]]- (9CI) (CA INDEX NAME)




RN 787591-74-6 CAPLUS

CN Urea, N-[4-[[8-(cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-N'-[2-(1-pyrrolidinyl)ethyl]]- (9CI) (CA INDEX NAME)



RN 787591-75-7 CAPLUS

CN Urea, N-[4-[[8-(cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-N'-[2-(4-morpholinyl)ethyl]]- (9CI) (CA INDEX NAME)



=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
12.98	186.51

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-1.50	-3.00

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 11:47:22 ON 02 MAR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAOTERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 MAR 2006 HIGHEST RN 875609-25-9

DICTIONARY FILE UPDATES: 1 MAR 2006 HIGHEST RN 875609-25-9

New CAS Information Use Policies, enter HELP USAOTERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.


REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UO/regprope.html>

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> Uploading C:\Program Files\Stnexp\Queries\IMIDAZOPYRAZINE KINASE INHIBITORS.etr



chain nodes :

10 11 12 20

ring nodes :

1 2 3 4 5 6 7 8 9 13 14 15 16 17 18

chain bonds :

1-11 2-10 4-20 8-12 9-13

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 13-14 13-18 14-15 15-16 16-17 17-18

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 4-20 5-6 5-7 6-9 7-8 8-9

exact bonds :

1-11 2-10 8-12 9-13

normalized bonds :

13-14 13-18 14-15 15-16 16-17 17-18

G1:C,H,O,S,P

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS  
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 20:CLASS

L7 STRUCTURE UPLOADED


=> que L7

L8 QUE L7

=> d 17

L7 HAS NO ANSWERS

L7 STR



THIS WAS NOT SEARCHED FULLY.

(ONLY SAMPLE SEARCH, BUT PREP ART FOUND)

Structure attributes must be viewed using STN Express query preparation.

=> s 17

SAMPLE SEARCH INITIATED 11:48:20 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 473 TO ITERATE

100.0% PROCESSED 473 ITERATIONS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 8156 TO 10764

PROJECTED ANSWERS: 93 TO 587

L9

17 SEA SSG SAM L7

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.88	187.39

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-3.00

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 11:48:26 ON 02 MAR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAOTERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Mar 2006 VOL 144 ISS 10  
FILE LAST UPDATED: 1 Mar 2006 (20060301/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

-- # 19  
L10 3 L9

-- # 110 not  
MISSING TERM AFTER L10 NOT  
Operators must be followed by a search term, L-number, or query name.

-- # 110 not 16  
L11 1 L10 NOT L6

-- d

L11 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS ON STN  
AN 2004:267339 CAPLUS  
DN 140:303700

TI Preparation and pharmaceutical compositions of novel imidazopyrazines as  
cyclin dependent kinase inhibitors

IN Paruch, Kamal; Guzi, Timothy J.; Dwyer, Michael P.; Doll, Ronald J.;

Girijavallabhan, Viyyoor M.; Mallams, Alan K.

SA Schering Corporation, USA

PO PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI NO 2004026877	A1	20040401	WO 2003-052909	20030919
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KO, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MK, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, NG, TD, TG				
CA 2499756	AA	20040401	CA 2003-2499756	20030919
US 2004063715	A1	20040401	US 2003-665005	20030919
US 6919341	B2	20050719		
AU 2003272476	A1	20040408	AU 2003-272476	20030919
EP 1543008	A1	20050622	EP 2003-754658	20030919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005130980	A1	20050616	US 2005-47524	20050131
PRAI US 2002-412997P	P	20020923		
US 2003-665005	A3	20030919		
WO 2003-US29209	W	20030919		
OS MARPAT 140:303700				

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

-- d abs hitarr


L11 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS ON STN  
G1



AB In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyrazine compds. of formula I [R = H, halo, (un)substituted-aryl, -heteroaryl, -cycloalkyl, etc.; R1 = H, halo or alkyl; R2 = halo, (un)substituted-alkyl, -aryl, -aryalkyl, etc.; R3 = H, (un)substituted-aryl, -heteroaryl, -heterocyclyl, etc.] as inhibitors of cyclin dependent kinases, methods of preparing such compds., pharmaceutical compns. containing one or more such compds., methods of preparing

pharmaceutical formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compds. or pharmaceutical compns. Thus, e.g., II was prepared by condensation of 8-chloro-3-methylimidazo[1,2-a]pyrazine with 4-(aminomethyl)pyridine. I possessed excellent CDK inhibitory properties, e.g., II demonstrated an IC50 value of 22.5  $\mu$ M.

IT 676359-65-2P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(drug candidate; preparation of imidazopyrazines as cyclin dependent kinase inhibitors)  
RN 676359-65-2 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-methyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



-- log hold  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST

SINCE FILE  
ENTRY  
17.07  
TOTAL  
SESSION  
204.46

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)  
CA SUBSCRIBER PRICE

SINCE FILE  
ENTRY  
-0.75  
TOTAL  
SESSION  
-3.75

SESSION WILL BE HELD FOR 60 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 12:03:51 ON 02 MAR 2006  
Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623ZCT

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR 7):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 CASREACT(R) - Over 10 million reactions available  
NEWS 4 DEC 14 2006 MeSH terms loaded in MEDLINE/UMEDLINE  
NEWS 5 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER  
NEWS 6 DEC 14 CA/Caplus to be enhanced with updated IPC codes  
NEWS 7 DEC 21 IPC search and display fields enhanced in CA/Caplus with the IPC reform  
NEWS 8 DEC 23 New IPCs SEARCH, DISPLAY, and SELECT fields in USP2FULL/USPAT2  
NEWS 9 JAN 13 IPC 8 searching in IPIPAT, IFIUDS, and IFICDB  
NEWS 10 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC  
NEWS 11 JAN 17 Pre-1988 INPI data added to MARPAT  
NEWS 12 JAN 17 IPC 8 in the WPI family of databases including WPIFV  
NEWS 13 JAN 30 Saved answer limit increased  
NEWS 14 JAN 31 Monthly current-awareness alert (SDI) frequency added to TULSA  
NEWS 15 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results  
NEWS 16 FEB 22 Status of current WO (PCT) information on STN  
NEWS 17 FEB 22 The IPC thesaurus added to additional patent databases on STN  
NEWS 18 FEB 22 Updates in EPPULL; IPC 8 enhancements added  
NEWS 19 FEB 27 New STN AnaVist pricing effective March 1, 2006  
NEWS 20 FEB 28 MEDLINE/UMEDLINE reload improves functionality  
NEWS 21 FEB 28 TOXCENTER reloaded with enhancements  
NEWS 22 FEB 28 REGISTRY/ZREGISTRY enhanced with more experimental spectral property data  
NEWS 23 MAR 01 INSPEC reloaded and enhanced  
NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V8.0c(EMO) AND V8.0c(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT <http://download.cas.org/express/v8.0-Discover/>  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 08:27:33 ON 03 MAR 2006

-- file reg  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST

SINCE FILE  
ENTRY  
0.21  
TOTAL  
SESSION  
0.21

FILE 'REGISTRY' ENTERED AT 08:27:57 ON 03 MAR 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 MAR 2006 HIGHEST RN 875609-25-9  
DICTIONARY FILE UPDATES: 1 MAR 2006 HIGHEST RN 875609-25-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartsSELECT searches.

\*\*\*\*\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.


REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

-- ...Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

--  
Uploading C:\Program Files\Stnexp\Queries\IMIDAZOPYRAZINE KINASE INHs.str



```
chain nodes :
10 11 12 20
ring nodes :
1 2 3 4 5 6 7 8 9 13 14 15 16 17 18
chain bonds :
1-11 2-10 4-20 8-12 9-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 13-14 13-18 14-15 15-16 16-17 17-18
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact bonds :
1-11 2-10 8-12 9-13
normalized bonds :
13-14 13-18 14-15 15-16 16-17 17-18
```

G1:C,H,O,S,P

Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS  
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 20:CLASS

L1 STRUCTURE UPLOADED

>> que L1

L2 OUR L1

>> d l1

L1 HAS NO ANSWERS

L1 STR

>> d 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS ON STN  
AN 2005:134601 CAPLUS  
DN 142:134621  
TI Preparation of aryl-substituted 8-aminoarylimidazo[1,2-a]pyrazines as  
kinase inhibitors for treatment of cancer and other conditions  
IN Sun, Connie Li; Liang, Congxin; Huang, Ping; Harris, G. Davis; Guan,  
Huiping  
PA Sugen, Inc., USA  
SO U.S. Pat. Appl. Publ., 119 pp., Cont.-in-part of U.S. Ser. No. 781,928.  
CODEN: USXXCO  
DT Patent  
LA English  
FAM.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005009832	A1	20050113	US 2004-845586	20040514
US 2004220189	A1	20041104	US 2004-781928	20040220
PRAI US 2003-448114P	P	20030220		
US 2003-508860P	P	20031007		
US 2004-781928	A2	20040220		
OS MARPAT 142:134621				

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS ON STN  
AN 2004:934327 CAPLUS  
DN 141:395578  
TI Preparation of aryl-substituted 8-aminoarylimidazo[1,2-a]pyrazines as  
kinase inhibitors for treatment of cancer and other conditions  
IN Sun, Connie Li; Liang, Congxin; Huang, Ping; Harris, G. Davis; Guan,  
Huiping  
PA Sugen, Inc., USA  
SO U.S. Pat. Appl. Publ., 76 pp.  
CODEN: USXXCO  
DT Patent  
LA English  
FAM.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004220189	A1	20041104	US 2004-781928	20040220
US 2005009832	A1	20050113	US 2004-845586	20040514
PRAI US 2003-448114P	P	20030220		
US 2003-508860P	P	20031007		
US 2004-781928	A2	20040220		
OS MARPAT 141:395578				

>> file reg


COST IN U.S. DOLLARS  
ENTRY  
FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 08:34:19 ON 03 MAR 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE 'HELP USAGETERMS' FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 1 MAR 2006 HIGHEST RN 875609-25-9  
DICTIONARY FILE UPDATES: 1 MAR 2006 HIGHEST RN 875609-25-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.



Structure attributes must be viewed using STN Express query preparation.

>> s l1  
SAMPLE SEARCH INITIATED 08:33:31 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 473 TO ITERATE

100.0% PROCESSED 473 ITERATIONS 14 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 8156 TO 10764  
PROJECTED ANSWERS: 56 TO 504

L3 14 SRA SSS SAM L1

>> file caplus  
COST IN U.S. DOLLARS  
ENTRY  
FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 08:33:35 ON 03 MAR 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE 'HELP USAGETERMS' FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is  
held by the publishers listed in the PUBLISHER (PB) field (available  
for records published or updated in Chemical Abstracts after December  
26, 1996), unless otherwise indicated in the original publications.  
The CA Lexicon is the copyrighted intellectual property of the  
American Chemical Society and is provided to assist you in searching  
databases on STN. Any dissemination, distribution, copying, or storing  
of this information, without the prior written consent of CAS, is  
strictly prohibited.

FILE COVERS 1907 - 3 Mar 2006 VOL 144 ISS 10  
FILE LAST UPDATED: 1 Mar 2006 (20060301/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.  
They are available for your review at:

<http://www.cas.org/infopolicy.html>

>> s l3

L4 2 L3

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

\*\*\*\*\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added. \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS  
for details.



REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

>> ...Testing the current file... screen

ENTER SCREEN EXPRESSION OR (END):end

>> Uploading C:\Program Files\Stnexp\Queries\IMIDAZOPYRAZINE KINASE INHs.str



```
chain nodes :
10 11 12 20
ring nodes :
1 2 3 4 5 6 7 8 9 13 14 15 16 17 18
chain bonds :
1-11 2-10 4-20 8-12 9-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 13-14 13-18 14-15 15-16 16-17 17-18
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact bonds :
1-11 2-10 8-12 9-13
normalized bonds :
13-14 13-18 14-15 15-16 16-17 17-18
```

G1:C,H,O,S,P

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS  
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 20:CLASS

L5 STRUCTURE UPLOADED

-- que L5

L6 QUE L5

-- s 16

SAMPLE SEARCH INITIATED 08:37:11 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1024 TO ITERATE

100.0% PROCESSED 1024 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 18561 TO 22399


PROJECTED ANSWERS: 0 TO 0

L7 0 SEA SSS SAM L5

-- d 15

L5 HAS NO ANSWERS

L5 STR



G1 C,H,O,S,P

Structure attributes must be viewed using STN Express query preparation.

--> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE TOTAL  
ENTRY SESSION

FULL ESTIMATED COST

2.64

9.55

STN INTERNATIONAL LOGOFF AT 08:37:55 ON 03 MAR 2006